RIGL: Rigel Pharma Company Value to Net Income
Rigel Pharmaceuticals (RIGL) develops innovative small-molecule therapies to combat oncological and hematological pathologies. Experienced management effectively balances product commercialization with research and development activities. The company's P/E trend demonstrates the market valuation of the asset, while the 2.70 value reflects this status. However, dependence on patents and the costs of testing new formulas hinder the achievement of full financial autonomy.
%20P%2FE%20Multiple&width=1200&height=400&colorIndex=0&v=mwczyyub.rjb-7czcsu8&start=20220704&end=20261112&filename=GURU_Markets_-_RIGL_-_Rigel-Pharmaceuticals_-_PE-Multiple "RIGL: Rigel Pharmaceuticals Business Payback Period 07/04/2022 - 11/12/2026 | 👁️GURU.Markets👁️")
Analytical breakdowns for Rigel Pharmaceuticals Inc (RIGL)
- price and consensus price forecast:
- market capitalization information:
- balance sheet net asset value indicators:
- debt and solvency information:
Total Debt to Equity Ratio Rigel Pharmaceuticals|RIGL - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Rigel Corp|RIGL - Company Debts|Debt to Book Value Ratio Rigel Pharmaceuticals, Inc.|RIGL - Company Long-Term Debts|Short-Term Debt Rigel Pharmaceuticals|Intermediate Coverage Ratio rigel.com
- earnings and market multiples details:
RIGL - Net Profit|Company Profit Forecast Rigel Pharmaceuticals|RIGL - P/E Multiple|Forward Price to Earnings Multiple Rigel Pharma|RIGL - PEG Multiple|Company Value to EBITDA Rigel Pharmaceuticals, Inc.|RIGL - Profit before payment of interest, taxes and amortization|Earnings per share for the last twelve months Rigel Pharmaceuticals|RIGL - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months rigel.com|RIGL - Earnings per share growth in current year|Net earnings per share change forecast for next year Rigel Pharmaceuticals
Comprehensive company analysis:rigel.com RIGL
Minimizing investment risks requires weighing market capitalization against the actual ability of Rigel Pharmaceuticals (RIGL) to generate net income, particularly in light of costs associated with the robotization of laboratory screening. By analyzing the current P/E ratio, an investor determines the business's payback period, assessing the extent to which the share price is justified by the company's current efficiency on a per-share basis.
Key competitors
P/E Multiple argenx.com|Price to Earnings Ratio BNTX (BioNTech)|ABVX (ABIVAX) - Company Value to Net Income|P/E Multiple ADMA (ADMA Bio)|Business Payback Period Protagonist Corp (PTGX)|IMVT - Price to Earnings Ratio|kiniksa.com (KNSA) - Price to Earnings Ratio|Grifols (GRFS) - Price to Earnings Ratio|Price to Earnings Ratio Adaptive Biotech|Price to Earnings Ratio CLDX|P/E Multiple Aurinia Corp|Price to Earnings Ratio BioCryst (BCRX)|veratx.com - Price to Earnings Multiple|P/E Multiple DNTH (Dianthus Therapeutics, Inc.)|Pharvaris NV (PHVS) - Market Cap to Earnings|ABCL - Price to Earnings Ratio|Company Value to Net Income TRML (Tourmaline)|PGEN: P/E Multiple|PHAR - Business Payback Period|NKTR (Nektar Therapeutics Inc.) - P/E Multiple|UPB - Market Cap to Net Income Ratio|P/E Multiple ZBIO|IMNM - Market Cap to Earnings|Price to Earnings Ratio Gossamer Bio, Inc. GOSS|kalvista.com - Price to Earnings Ratio|SEPN: Price to Earnings Ratio|Company Value to Net Income PVLA (Pieris Pharma)|Savara Corp (SVRA) - Price to Earnings Ratio|Market Cap to Net Income ANAB (AnaptysBio Inc.)|ATXS (Astria Therapeutics) - P/E Multiple|ENGN: Company Value to Net Income|P/E Multiple RAPT|P/E Multiple aerovatetx.com (JBIO)|Price to Earnings Ratio Aclaris ACRS|Company Value to Net Income KYTX|TLSA - Price to Earnings Ratio|cabalettabio.com (CABA) - Price to Earnings Ratio|VTYX: P/E Multiple|Theratechnologies, Inc. (THTX) - P/E Multiple|AVTX (Avalo Therapeutics Inc.) - P/E Multiple|Price to Earnings Ratio Eledon Pharmaceuticals, Inc (ELDN)|P/E Multiple AGEN|CLYM - Market Cap to Earnings|Zura Bio - Price to Earnings Ratio|P/E Multiple aTyr Pharma Inc ATYR|ADAG: Price to Earnings Ratio|ImageneBio Inc - Market Price to Net Income Ratio|STTK: P/E Multiple|EQ - Business Payback Period|CNTB (Connect Biopharma Holdings) - P/E Multiple|Price to Earnings Ratio Immunic Inc (IMUX)|P/E Multiple ATRA|P/E Multiple inflarx.de (IFRX)|Price to Earnings Ratio X4 Pharmaceuticals XFOR|Adicet Bio Inc. - Price to Earnings Ratio|CELU - Price to Earnings Ratio|Business Payback Period INmune Bio Inc INMB|Barinthus Bio (BRNS) - Price to Earnings Ratio|Kezar Life Sciences Inc - Company Value to Net Income|SABS (SAB Biotherapeutics) - P/E Multiple|akaritx.com (AKTX) - Business Payback Period|P/E Multiple ENLV|q32bio.com (QTTB) - Market Cap to Net Income Ratio|Price to Earnings Ratio GeoVax Labs Inc GOVX|Edesa Biotech Corp - Price to Earnings Ratio|IBIO - Price to Earnings Ratio|Market Cap to Net Income CARM|XTLB: P/E Multiple|Bolt Biotherapeutics, Inc. - Company Value to Net Income|HCWB (HCW Biologics, Inc.) - P/E Multiple|P/E Multiple Aptevo|Price to Earnings Ratio AIM ImmunoTech Inc. (AIM)|ADTX (aditxt.com) - Company Value to Net Income|Price to Earnings Ratio GRI Bio GRI|XRTX - Price to Earnings Ratio|ReShape Lifesciences - P/E Multiple|REVB - P/E Multiple|INDP (Indaptus Therapeutics) - Price to Earnings Ratio|scinai.com - Company Value to Net Income|CALI (CalciMedica Inc) - P/E Multiple|Affimed Therapeutics (AFMD) - Business Payback Period|Price to Earnings Ratio Allakos Inc. (ALLK)|Price to Earnings Ratio hookipapharma.com HOOK|Price to Earnings Ratio IGM Biosciences IGMS|ITOS - Price to Earnings Ratio|OCEA: Price to Earnings Ratio|TCBP - P/E Multiple|Third Harmonic Bio, Inc (THRD) - Price to Earnings Ratio
